(Q40816221)

24 September 2017

title

Modeling the hepatitis C virus epidemic in France (English)

1 reference

24 September 2017

1 reference

1 reference

3

Poynard T

1 reference

24 September 2017

Deuffic S

1

1 reference

24 September 2017

Buffat L

series ordinal

2

1 reference

24 September 2017

Valleron AJ

series ordinal

4

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

24 September 2017

1 reference

24 September 2017

volume

29

1 reference

24 September 2017

issue

5

1 reference

24 September 2017

page(s)

1596-1601

1 reference

Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Increase in primary liver cancer in the UK, 1979-94

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Trends in primary liver cancer

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Minimum size of the acquired immunodeficiency syndrome (AIDS) epidemic in the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Transmission dynamics and epidemiology of BSE in British cattle

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Incubation period of AIDS in patients infected via blood transfusion.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Incubation time for AIDS from French transfusion-associated cases

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Estimating HIV prevalence and projecting AIDS incidence in the United States: a model that accounts for therapy and changes in the surveillance definition of AIDS

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Antibody to hepatitis C virus in post-transfusion hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Epidemiology and long term prognosis of hepatitis C virus infection in Japan

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Histopathology of chronic hepatitis C in relation to epidemiological factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Hepatitis C virus and hepatocellular carcinoma in France: detection of antibodies using two second generation assays

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290528

7 January 2021

Identifiers

DOI

10.1002/HEP.510290528

1 reference

24 September 2017

1 reference